Aldeia Cannabis, a Canadian medical cannabis company focused on the cultivation, processing, extraction and R&D of high quality medical cannabis, has achieved a crucial milestone by receiving from Infarmed I.P. (Portuguese Health Authority) a pre-license for the cultivation, import and export of medical cannabis. As expected, the Health Authority in Portugal has been very collaborative and supportive during this time (especially in light of the COVID-19 constraints and restrictions), again confirming the organizations views that Portugal is the right choice of jurisdiction for its European operations, in terms of legal & regulatory matters.
Following a detailed evaluation of its business plan, Aldeia has received clear recognition of the highest standards and quality of its project. With a team of highly experienced professionals in medical cannabis cultivation and processing, EU-GMP manufacturing, and a pharmaceutical go-to- market strategy, Aldeia is competitively positioned in the global cannabis industry. “The team has been exceptional during the entire process, developing an ambitious but realistic project, one that is adapted to what's been missing in the market” said Kyle Leite, Founder & CEO of Aldeia Cannabis. “Team members are simultaneously investors, thus we are all highly commiTed to the development of a sustainable business model. Applying our experience from previous projects in the cannabis industry, we want to start small and scale the business in alignment with the European market’s growth”.
With a unique indoor vertical cultivation approach, Aldeia is set to disrupt the European market with its high quality medicinal products, making the best use of its team’s experience in designing and implemen- ting successful marketing strategies for varied products segments within the cannabis industry. “We believe that in this industry’s infancy stage, teaching healthcare professionals about the benefits and training on how to best use medical cannabis, while working hand-in-hand to collect additional clinical information is critical to overcome the partial lack of confidence and credibility this market still has in Portugal and across Europe” added Mr. Leite.
Aldeia has regular contacts with distributors across Europe, Canada, Israel and Morocco and has signed multiple leTers of intent & supply agreements covering majority of its future production capacity. Kyle Leite added: “We will use our thorough medical cannabis go-to-market experience to ensure that our high-quality products will be available to all patients that need them.”
Aldeia will now focus on the next phases of constructing its planned state-of-the-art aeroponics small-batch Medical Cannabis facility in Central Portugal. The new facility, once completed, will comprise of a fully automated indoor facility which meets the Good Agricultural Collection Practices (“GACP“) and GMP regulations, for the production and transformation of medicinal cannabis. "The 9300m2 double storey building was designed to achieve maximum efficiencies, and will include full LED cultivation lighting, recirculating water systems and solar energy. Being able to produce over 19,000Kg annually from just 2900m2 of flowering space positions us to be one of the most efficient producers in the industry" says Leite.
Aldeia Cannabis is a Canadian medical cannabis company operating in Portugal, focused on the cultivation, processing and extraction of high quality small-batch medical cannabis. The team combines 50+ years of business management experience and 25+ years operating medical cannabis cultivation sites in Canada. Additionally, Aldeia will focus on the research and development of new medical delivery forms that will allow medical cannabis to target new clinical areas and different patient profiles, aligning it with existing unmet clinical needs.
For more information:
Aldeia Cannabis
Chantal Peralta
(416)799-6769
[email protected]
aldeiacannabis.eu